Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Camp4 Therapeutics CorpCAMP · Entity 1161 | Director | June 25, 2025 | June 27, 2025 |
| GENOCEA BIOSCIENCES, INC.GNCA · Entity 12635 | Director | July 01, 2021 | July 02, 2021 |
| Korsana Biosciences, Inc.CYCN · Entity 7698 | Director | March 25, 2025 | March 27, 2025 |
| Pulmatrix, Inc.PULM · Entity 8249 | Director | January 26, 2023 | January 30, 2023 |
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Camp4 Therapeutics Corp
Report date June 25, 2025 · Filed June 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.56 · Expires 2035-06-24 | Direct | 9,000 |
Reported balance
After 2025-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-25 · Grant · Acquired 9,000 · Balance 9,000 F1: The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date.
GENOCEA BIOSCIENCES, INC.
Report date July 01, 2021 · Filed July 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.33 · Expires 2031-07-01 | Direct | 15,000 |
Reported balance
After 2021-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-01 · Grant · Acquired 15,000 · Balance 15,000 F1: 100% of the options are scheduled to vest on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the options are scheduled to vest on the first anniversary of the grant date.
Korsana Biosciences, Inc.
Report date March 25, 2025 · Filed March 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,740 |
Reported balance
After 2025-03-25 transaction · row 1
1 source rowRow 1 · 2025-03-25 · Grant · Acquired 9,090 · Balance 30,740 F1: On March 25, 2025, the reporting person purchased directly from the Issuer 9,090 shares of Common Stock for a total purchase price of approximately $25,000 (or $2.75 per share) in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 21, 2025 by and among the Issuer and the investors named therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 25, 2025, the reporting person purchased directly from the Issuer 9,090 shares of Common Stock for a total purchase price of approximately $25,000 (or $2.75 per share) in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 21, 2025 by and among the Issuer and the investors named therein.
Pulmatrix, Inc.
Report date January 26, 2023 · Filed January 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.99 · Expires 2033-01-26 | Direct | 2,436 |
Reported balance
After 2023-01-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-26 · Grant · Acquired 2,436 · Balance 2,436 F1: The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 26, 2023, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 26, 2023, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan.
Voyager Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.43 · Expires 2036-06-09 | Direct | 30,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 30,000 · Balance 30,000 F1: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 11, 2026 20:03 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001104659-26-072923 · tm2617547-5_4seq1.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-09 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director. Read SEC document |
| June 25, 2025 Filed Jun 27, 2025 20:03 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001736730-25-000059 · wk-form4_1751054575.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2035-06-24 F1 · derivative.exercise_date: The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 01:00 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $3.28 | $0.00 |
DisclosureSEC source: 0001104659-25-056562 · tm2517191-3_4seq1.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director. Read SEC document |
| March 25, 2025 Filed Mar 27, 2025 20:20 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 9,090 | $2.75 | $24,997.50 |
DisclosureSEC source: 0000950170-25-046099 · ownership.xml · nonDerivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,740 F1 · shares: On March 25, 2025, the reporting person purchased directly from the Issuer 9,090 shares of Common Stock for a total purchase price of approximately $25,000 (or $2.75 per share) in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 21, 2025 by and among the Issuer and the investors named therein. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:16 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $8.70 | $0.00 |
DisclosureSEC source: 0001104659-24-069658 · tm2416702-3_4seq1.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director. Read SEC document |
| June 06, 2023 Filed Jun 7, 2023 20:38 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $12.57 | $0.00 |
DisclosureSEC source: 0001104659-23-068925 · tm2317994-5_4seq1.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2033-06-06 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:05 UTC | Pulmatrix, Inc. PULM · Entity 8249 | GrantStock Option (Right to Buy) · Derivative | 2,436 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001493152-23-002917 · ownership.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,436 Underlying: Common Stock · 2,436 shares Expires 2033-01-26 F1 · derivative.exercise_date: The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 26, 2023, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| July 14, 2022 Filed Jul 18, 2022 21:32 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 13,891 | $6.70 | $93,069.70 |
DisclosureSEC source: 0001104659-22-080576 · tm2221315-1_4seq1.xml · nonDerivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,314 F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on July 13, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on July 13, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.70 to $6.74, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 20:37 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $5.27 | $0.00 |
DisclosureSEC source: 0001104659-22-069345 · tm2218013-3_4seq1.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2032-06-06 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 14:39 UTC | Pulmatrix, Inc. PULM · Entity 8249 | GrantStock Option (Right to Buy) · Derivative | 36,833 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001493152-22-002679 · ownership.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,833 Underlying: Common Stock · 36,833 shares Expires 2032-01-27 F1 · derivative.exercise_date: The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments with the first tranche vesting on January 27, 2022, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| January 13, 2022 Filed Jan 19, 2022 01:04 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 161,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001104659-22-005020 · tm223208-4_4seq1.xml · derivative · entry 2 Higgins Michael J · CIK 0001478521 · Director · Interim President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,000 Underlying: Common Stock · 161,000 shares Expires 2032-01-13 F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. 1/5th of the shares of common stock underlying the option vest on each of February 12, 2022, March 12, 2022, April 12, 2022, May 12, 2022 and June 2, 2022, subject to the Reporting Person's continued service as an interim executive officer. Read SEC document |
| January 13, 2022 Filed Jan 19, 2022 01:04 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantCommon Stock | 45,205 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-005020 · tm223208-4_4seq1.xml · nonDerivative · entry 1 Higgins Michael J · CIK 0001478521 · Director · Interim President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,205 F1 · shares: Consists of shares of common stock issuable under an aggregate of 45,205 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, January 13, 2022. 100% of the shares of common stock underlying the RSU award vest on the six-month anniversary of such vesting commencement date, subject to the Reporting Person's continued service as a director, officer, or otherwise. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 15:49 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001457612-21-000076 · wf-form4_162524093242062.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-07-01 F1 · derivative.exercise_date: 100% of the options are scheduled to vest on the first anniversary of the grant date. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 20:32 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001104659-21-077076 · tm2118780d4_4seq1.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director · Interim President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. The option vests over one year with 1/12th of the shares of common stock underlying the option vesting upon the one-month anniversary of the Vesting Commencement Date and an additional 1/12th of the shares of common stock underlying the option vesting at the end of each successive one-month period, subject to the Reporting Person's continued service. Read SEC document |
| January 28, 2021 Filed Feb 2, 2021 02:45 UTC | Pulmatrix, Inc. PULM · Entity 8249 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.47 | $0.00 |
DisclosureSEC source: 0001493152-21-002325 · ownership.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-01-28 F1 · derivative.exercise_date: The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on January 28, 2021, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 20:10 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001457612-20-000101 · wf-form4_159259744015850.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-18 F1 · derivative.exercise_date: The option vests 100% on the first anniversary of the grant date. Read SEC document |
| June 04, 2020 Filed Jun 5, 2020 20:17 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $11.79 | $0.00 |
DisclosureSEC source: 0001104659-20-070329 · a4.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-04 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 18:12 UTC | Pulmatrix, Inc. PULM · Entity 8249 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001493152-20-006979 · ownership.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-04-21 F1 · derivative.exercise_date: The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on May 21, 2020, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| April 02, 2020 Filed Apr 6, 2020 23:02 UTC | Pulmatrix, Inc. PULM · Entity 8249 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0000899243-20-010333 · doc4.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-04-02 F1 · derivative.exercise_date: The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on May 2, 2020, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 22:19 UTC | Pulmatrix, Inc. PULM · Entity 8249 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0000899243-20-001099 · doc4.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-01-09 F1 · derivative.exercise_date: The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on January 9, 2020, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| July 18, 2019 Filed Jul 19, 2019 20:08 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 5,625 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001457612-19-000112 · wf-form4_156356689452549.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,625 Underlying: Common Stock · 5,625 shares Expires 2029-07-18 F1 · derivative.exercise_date: The option vests 100% on the first anniversary of the grant date. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 22:58 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $24.68 | $0.00 |
DisclosureSEC source: 0001104659-19-035997 · a4.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-13 F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service. Read SEC document |
| May 16, 2019 Filed May 20, 2019 20:10 UTC | Pulmatrix, Inc. PULM · Entity 8249 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0000899243-19-014134 · doc4.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-05-16 F1 · derivative.exercise_date: The option vests in forty-eight (48) equal monthly installments on the 16th day of each month, with the first tranche vesting on June 16, 2019, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| June 21, 2018 Filed Jun 26, 2018 00:09 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001457612-18-000072 · wf-form4_152997174642723.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-06-21 F1 · derivative.exercise_date: The option vests 100% on the first anniversary of the grant date. Read SEC document |
| June 14, 2018 Filed Jun 19, 2018 00:49 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $21.64 | $0.00 |
DisclosureSEC source: 0001104659-18-040894 · a4.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-14 F1 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service. Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 22:02 UTC | Pulmatrix, Inc. PULM · Entity 8249 | GrantStock Option (Right to Buy) · Derivative | 124,000 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0000899243-18-015302 · doc4.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,000 Underlying: Common Stock · 124,000 shares Expires 2028-06-05 F1 · derivative.exercise_date: One-fourth (1/4) of the option vested on June 5, 2018 and the remainder vests in thirty-six (36) equal monthly installments with 2.083% vesting on the last day of each of the next thirty-six (36) months that follow June 5, 2018, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| June 29, 2017 Filed Jun 30, 2017 20:02 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.06 | $0.00 |
DisclosureSEC source: 0001104659-17-042940 · a4.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-29 F1 · derivative.exercise_date: This stock option award was granted under Voyager Therapeutics, Inc.'s 2015 Stock Option and Incentive Plan pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy and will vest in full upon the first anniversary of the grant, subject to Mr. Higgins' continued service on the Board of Directors. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 20:59 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $5.34 Strike: $5.34 | $80,100.00 |
DisclosureSEC source: 0001478521-17-000002 · wf-form4_149756033534261.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-13 F1 · derivative.exercise_date: The option vests 100% on the first anniversary of the grant date. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 22:54 UTC | Pulmatrix, Inc. PULM · Entity 8249 | GrantStock Option (Right to Buy) · Derivative | 4,400 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0000899243-17-008419 · doc4.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 Underlying: Common Stock · 4,400 shares Expires 2027-03-20 F1 · derivative.exercise_date: The option vests as to 25% on March 20, 2018 and the remaining 75% vests in thirty-six (36) equal monthly installments with 2.083% vesting for each of the next thirty-six (36) months that follow March 20, 2018, subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| February 03, 2016 Filed Apr 23, 2020 18:14 UTC Amendment | Pulmatrix, Inc. PULM · Entity 8249 | GrantStock Option (Right to Buy) · Derivative | 8,800 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001493152-20-006980 · ownership.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,800 Underlying: Common Stock · 8,800 shares Expires 2026-02-03 F1 · date: The reporting person's original Form 4 erroneously listed the transaction date as February 3, 2026. The share amounts, the share price, and the amount of securities beneficially owned reported above do not give effect to a 1-for-10 reverse stock split that occurred on February 5, 2019. F2 · derivative.exercise_date: The option vests as to 25% on February 3, 2017 and the remaining 75% vests in thirty-six (36) equal monthly installments with 2.083% vesting on the last day of each of the next thirty-six (36) months that follow February 3, 2017, subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.